Tumour suppressor genes encode proteins that actively restrain cell proliferation, promote DNA repair, or eliminate damaged cells. Unlike oncogenes, which require only a single activating mutation, tumour suppressors typically require biallelic inactivation (Knudson's two-hit hypothesis) before their protective effect is lost. Three tumour suppressor networks dominate oncogenesis: the p53 network (integrating DNA damage and oncogenic stress signals), the pRb network (controlling the G1/S restriction point), and the PTEN/PI3K network (counteracting survival signalling). These networks are deeply interconnected — p53 regulates MDM2 (which regulates p53 through feedback), PTEN loss activates AKT which degrades p53 through MDM2, and CDKN2A deletion removes the guardians of both pRb and p53 simultaneously.
The three major tumour suppressor networks form an integrated defence system: p53 detects DNA damage and oncogenic stress, imposing arrest or apoptosis via p21 and BAX/PUMA; pRb enforces the G1/S restriction point by sequestering E2F transcription factors; and PTEN opposes survival signalling through PIP3 dephosphorylation. These networks are reinforced by cross-talk: p53 represses BCL2 (pro-survival), activates pRb targets indirectly through p21, and is stabilised by ARF (CDKN2A). Loss of any one network dramatically accelerates loss of the others through relieved selective pressure.
The three major tumour suppressor networks form an integrated defence system: p53 detects DNA damage and oncogenic stress, imposing arrest or apoptosis via p21 and BAX/PUMA; pRb enforces the G1/S restriction point by sequestering E2F transcription factors; and PTEN opposes survival signalling through PIP3 dephosphorylation. These networks are reinforced by cross-talk: p53 represses BCL2 (pro-survival), activates pRb targets indirectly through p21, and is stabilised by ARF (CDKN2A). Loss of any one network dramatically accelerates loss of the others through relieved selective pressure.
pRb helps enforce the G1 restriction point by binding E2F transcription factors and recruiting chromatin regulators to restrain S-phase genes. Cyclin D–CDK4/6 activity, limited by p16INK4a, changes pRb phosphorylation and E2F control. Many cancers alter this axis, but the affected node and functional consequence differ by tumour.
PTEN dephosphorylates PIP3→PIP2, opposing PI3K-generated PIP3 and limiting AKT activation. AKT drives survival (BAD phosphorylation), p53 degradation (MDM2 activation), and proliferation (GSK3β inactivation, cyclin D1 stabilisation). PTEN loss therefore simultaneously activates survival, proliferation, and p53 suppression.
The CDKN2A locus encodes p16INK4a (inhibiting CDK4/6 → protecting pRb) and p14ARF (sequestering MDM2 → protecting p53). This dual-gene locus provides coordinated protection of both networks. Homozygous deletion at a single genomic locus disables both tumour suppressor circuits simultaneously — explaining the extraordinary selective advantage and frequency of CDKN2A deletion.
BRCA1 integrates with the p53 network (ATM→BRCA1→HR repair) to ensure DSBs are repaired faithfully before S phase amplifies mutations. BRCA1 loss forces error-prone NHEJ repair, generating structural variants (deletions, translocations) that drive genomic instability and accumulate additional tumour suppressor losses over time.
Loss of one control system can create dependencies elsewhere, but the strongest examples remain context-specific. BRCA1/2 loss can support a PARP-inhibitor hypothesis in defined settings; PTEN or TP53 loss has motivated PI3K-, ATR- and checkpoint-directed studies without creating one universal synthetic-lethal rule. Biomarker, assay and tumour lineage determine whether pathway logic becomes clinical evidence.
Tumours often alter more than one growth-control system, but the number, order and clonality of events vary. Pathogenic germline variants in TP53, BRCA1/2, PTEN or RB1 can cause distinct inherited cancer-predisposition syndromes; penetrance is gene-, variant-, age- and sex-dependent and is not equivalent to certainty. Most tumour-only findings are somatic and do not by themselves diagnose an inherited syndrome.
Restoring a lost tumour suppressor remains difficult. MDM2 inhibition generally requires functional p53 and cannot repair every TP53 variant; mutant-p53 reactivation remains investigational. Synthetic-lethal and pathway-dependency strategies have indication-specific evidence, strongest in defined BRCA/HRD contexts. Comprehensive profiling describes alterations, but treatment benefit still requires tumour-specific clinical evidence and a current regulatory or guideline source.
Why is it so common to see multiple tumour suppressor losses in the same tumour?
Loss of the first tumour suppressor generates genomic instability that accelerates acquisition of subsequent mutations. For example, TP53 loss prevents apoptosis after DNA damage, allowing cells with additional tumour suppressor mutations to survive. BRCA1 loss generates structural variants that can delete CDKN2A or RB1. Each sequential loss accelerates the accumulation of subsequent losses through elevated mutation rates and reduced apoptotic surveillance.
What is the two-hit hypothesis and does it always apply?
Knudson's model explains how loss of both functional alleles can remove tumour-suppressor activity, classically illustrated by RB1. One event may be inherited and the second acquired, or both may be somatic. Real tumours add complexity through haploinsufficiency, dominant-negative variants, promoter methylation, structural changes and partial loss of function, so allele state and mechanism should be evaluated for the specific gene rather than assuming every tumour suppressor follows an identical two-hit rule.
Compare the p53 and RB tumour-suppressor systems, see how CDKN2A connects them, and learn why MDM2 amplification is not the same as a TP53 mutation.
Understand how tumor suppressor genes — including TP53, BRCA1, PTEN, and RB1 — act as the genome's brakes, and what happens when they are lost in cancer.
Understand BRCA1 in homologous recombination, how germline and tumour findings differ, what HRD can and cannot establish, and why PARP evidence is context-specific.
Understand TP53 loss of function, dominant-negative effects, hotspot mutations, p53 immunohistochemistry limits, inherited-risk context and experimental strategies.
How CDKN2A encodes two structurally unrelated tumor suppressors from the same locus, simultaneously protecting the pRb and p53 pathways, and why its deletion is so devastating in cancer.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
Homologous Recombination Repair
Homologous recombination (HR) repairs DNA double-strand breaks primarily in S/G2, when a sister chromatid is available a…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway integrates growth-factor, nutrient and energy signals to regulate cell survival, growth and me…
EGFR–KRAS–BRAF–MEK–ERK Signalling Pathway in Cancer
The EGFR signalling pathway converts extracellular EGF binding into intracellular proliferative and survival signals via…